SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Pediatric stiff-person syndrome and related disorders: A systematic review.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStiff-person syndrome (SPS) is a rare neuromuscular autoimmune disorder with significant diagnostic and treatment challenges, particularly in pediatric patients. Current understanding of pediatric SPS is limited; therefore, this systematic review aims to analyze the clinical profile, comorbidities, and treatment responses in these cases.
methodsA systematic review was conducted following PRISMA guidelines. Literature from five databases was searched up to March 2025, identifying cases of pediatric SPS (age ≤ 20 years). A total of 961 studies were screened, resulting in 49 cases from 41 reports being included. Data on demographics, symptoms, comorbidities, treatment, and outcomes were analyzed.
resultsThe 49 cases were distributed across 15 countries, with the highest representation from the USA (44.89%, n = 22). The median age was 12 years (IQR: 7-17), with a nearly equal male-to-female ratio (51.02% male). Comorbidities were present in 55.1% (n = 27), with type 1 diabetes mellitus (18.36%, n = 9) and thyroid dysfunction (14.28%, n = 7) being the most common. SPS subtypes included mainstream SPS (65.3%, n = 32), PERM (22.44%, n = 11), and stiff-limb syndrome (8.16%, n = 4). Benzodiazepines, primarily diazepam, were the most commonly used first-line therapy (51.02%, n = 25). Adjunctive treatments included corticosteroids (24.48%, n = 12), IVIG (18.36%, n = 9), and rituximab (14.28%, n = 7). Persistent symptoms were noted in 26.53% (n = 13) of cases.
conclusionThis study highlights the clinical heterogeneity and autoimmune nature of pediatric SPS. A proposed treatment protocol which may guide clinicians has been formulated.
Indexed as
Identifiers
40826302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.